Commonly used TKIs in the treatment of CML, like imatinib and dasatinib, interfere noncompetitively with monocarboxylate transporter 8 (MCT8), a key protein responsible for the cellular uptake of thyroid hormones (Figure 3). This evidence concerns the gene TG and chronic myelogenous leukemia, BCR-ABL1 positive.